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Abstract
Objective: Regulatory T cells (Treg) play a critical role in the prevention of autoimmunity, and the suppressive activity of
these cells is impaired in rheumatoid arthritis (RA). The aim of the present study was to investigate function and properties
of Treg of RA patients in response to purified polysaccharide glucuronoxylomannogalactan (GXMGal).
Methods: Flow cytometry and western blot analysis were used to investigate the frequency, function and properties of Treg
cells.
Results: GXMGal was able to: i) induce strong increase of FOXP3 on CD4+ T cells without affecting the number of
CD4+CD25+FOXP3+ Treg cells with parallel increase in the percentage of non-conventional CD4+CD252FOXP3+ Treg cells; ii)
increase intracellular levels of TGF-b1 in CD4+CD252FOXP3+ Treg cells and of IL-10 in both CD4+CD25+FOXP3+ and
CD4+CD252FOXP3+ Treg cells; iii) enhance the suppressive activity of CD4+CD25+FOXP3+ and CD4+CD252FOXP3+ Treg cells
in terms of inhibition of effector T cell activity and increased secretion of IL-10; iv) decrease Th1 response as demonstrated
by inhibition of T-bet activation and down-regulation of IFN-c and IL-12p70 production; v) decrease Th17 differentiation by
down-regulating pSTAT3 activation and IL-17A, IL-23, IL-21, IL-22 and IL-6 production.
Conclusion: These data show that GXMGal improves Treg functions and increases the number and function of
CD4+CD252FOXP3+ Treg cells of RA patients. It is suggested that GXMGal may be potentially useful for restoring impaired
Treg functions in autoimmune disorders and for developing Treg cell-based strategies for the treatment of these diseases.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease charac-
terized by destructive joint inflammation. The synovial inflamma-
tion is characterized by non-specific infiltration of both lympho-
cytes and innate immune cells, such as synoviocytes, macrophages
and neutrophils [1]. RA is generally considered to be an
autoimmune disease in which pathogenic T cells such as T helper
(Th)1 and Th17 cells play an important role [2]. An exciting
aspect of Th17 cell homeostasis is the reciprocal relationship with
regulatory T cells (Treg), whose imbalance is believed to play a
major role in the development of autoimmune disease [3–6]. Treg
were originally identified by high surface expression of CD25 [7,8]
and subsequently by the forkhead box protein P3 (FOXP3)
transcriptional factor, which controls their development and
suppressive function [9,10]. Interestingly, it was suggested that
activated FOXP3+ non-Treg cells may be a reservoir of silent Treg
that regain their function following activation [11]. The data on
the effective number of Treg cells in RA patients are inconsistent.
Some studies report a decreased number of Treg cells in the blood
of RA [12], while others report increased numbers of Treg cells
[13], however it is clear that Treg cells appear unable to suppress
inflammation in the rheumatoid joints [14]. Thus, paradoxically,
CD4+CD25+ T cells, including CD4+CD25+FOXP3+ Treg cells,
circulate in RA patients despite the still ongoing inflammation
[13,14]. The capacity of Treg cells to suppress several arthritic
responses both in humans and animal models makes them
potential therapeutic targets in arthritic conditions such as RA
[15]. A prior study suggested that the therapeutic efficacy of
methotrexate (MTX), the current ‘‘gold standard’’ treatment in
experimental RA, was partly attributed to the increased develop-
ment of CD4+CD25+ Treg cells [16]. Furthermore, anti-rheumatic
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biotechnological therapies may offer a means of restoring the Th17/
Treg cell balance in favor of Treg, thereby re-establishing immune
tolerance [6]. It has been demonstrated that some fungal products,
such as those from Cryptococcus neoformans (C. neoformans),
directly induce lymphocytes apoptosis [17]. Accordingly, we
demonstrated that glucuronoxylomannogalactan (GXMGal), a
purified capsular polysaccharide from the opportunistic fungus C.
neoformans [18], directly induce apoptosis of activated lymphocytes
[19]. This was recently evidenced also using activated RA T cells
producing IL-17A suggesting the potential role of GXMGal in
fighting deleterious Th17 cells [20]. In light of this finding, the aim
of this study was to understand whether GXMGal could restore the
Th17/Treg balance, both by dampening Th17 response [20] and
modulating Treg cell suppressive capacity.
Methods
Cryptococcal polysaccharide and other reagents
RPMI-1640 with L-glutamine, FCS and penicillin streptomycin
solution were obtained from EuroClone S.p.A. (Milan, Italy).
Brefeldin A, PHA, dexametasone (DEX), MTX, the inhibitor of
pSTAT3 (FLLL31) and hypotonic propidium iodide solution (PI)
were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Monoclonal antibodies (mAbs) to human CD3 and CD28 were
obtained from ImmunoTools GmbH (Friesoythe, Germany).
GXMGal [21], known until recently as galactoxylomannan, was
purified as described elsewhere [22,23]. The dose of GXMGal was
chosen on the basis of our previous published data [24]. All
reagent and media were negative for endotoxin, as assessed by
Limulus amebocyte lysate assay (QCL-1000, BioWhittaker, VWR
International p.b.i., Milan, Italy).
Subjects
Thirty patients with established RA according to the American
College of Rheumatology classification criteria [25] and followed
up at the Rheumatology Unit of the Perugia University, were
included in the study. This cohort included 20 women and 10 men
with a mean age of 5468 years (mean 6 SD) and disease duration
of 1266 years. The mean Disease Activity Score, as evaluated
including 28 swollen and tender joint count (DAS28), was 361.2
at the time of sample collection. All patients were MTX naı¨ve and
were receiving other synthetic or biologic disease-modifying anti-
rheumatic drugs in monotherapy (leflunomide: nu 11, hydroxy-
chloroquine: nu 16, tocilizumab: nu 3). Fourteen patients were also
receiving low doses of corticosteroids (5 mg/day of prednisone or
equivalent). Fifteen healthy subjects matched for age and sex acted
as normal control (Control). Written informed consent was
obtained from all subjects prior to sample collection in accordance
with the Declaration of Helsinki. Local Ethical Committee CEAS
(Comitato Etico delle Aziende Sanitarie, Umbria, Italy) approval
was received for the whole study (AR-2 n. 1874/12).
Isolation of cells and culture condition
Heparinized venous blood was obtained from Control and RA
patients. Peripheral blood mononuclear cells (PBMC) were
separated by density gradient centrifugation on Ficoll-Hypaque
(EuroClone). PBMC were incubated with mAb-conjugated
MicroBeads to human CD4 (Miltenyi Biotec) and CD4+ T
lymphocytes were purified by magnetic separation. Purity of
separated CD4+ T cells was .90% as detected by cytofluorimetric
analysis. CD4+CD25+ and CD4+CD252 cells were purified from
CD4+ T lymphocytes using the CD4+CD25+ Treg cell isolation kit
(Miltenyi Biotec) according to manufacturer’s instructions. Unless
otherwise specified, cells were seeded in 48 or 96-well culture
plates pre-coated with mAbs to CD3 plus CD28 (both 2 mg/ml)
and activated for 30 min with soluble mAbs to CD3 plus CD28
(both 3 mg/ml) (ImmunoTools) in RPMI-1640+10% FCS (com-
plete medium) at 37uC plus 5% CO2. After activation cells were
washed and stimulated as described below.
Cytokine Production
Activated PBMC (56106/ml) were incubated for 2, 18 and 72 h
in the presence or absence of GXMGal (10 mg/ml), MTX (10 ng/
ml) [26], DEX (10 nM) [27] or FLLL31 (5 mM) [20]. The
supernatants were collected and cytokines were tested by specific
ELISA assays (all from eBioscience, San Diego, CA). Cytokine
titers were calculated relative to standard curves.
Western Blot Analysis
Activated PBMC or CD4+ T cells (both 56106/ml) were
incubated for different times in the presence or absence of
GXMGal (10 mg/ml), MTX (10 ng/ml), DEX (10 nM) or
FLLL31 (5 mM). After incubation, proteins were extracted and
subjected to western blotting as previously described [20]. The
membranes were incubated overnight with polyclonal Abs to
pSTAT3 (goat; Tyr 705), STAT3 (rabbit), FOXP3 (rabbit), T-bet
(rabbit) (all dilution 1/200; all Santa Cruz Biotechnology,
Delaware Avenue, Santa Cruz, CA) in blocking buffer. Immuno-
reactive bands were visualized and quantified by Chemidoc
Instrument (Bio-Rad Laboratories, Hercules, CA) [28].
Flow Cytometry Analysis
Activated PBMC (16106/ml) were incubated for 2 or 18 h in
the presence or absence of GXMGal (10 mg/ml) or MTX (10 ng/
ml). After incubation, cells were fixed with 1.5% formalin for
10 min at room temperature (RT), washed and incubated with
FITC-labelled mAb to human CD4, APC-labelled mAb to human
CD25 (both mouse IgG1 isotype; 2 ml/tube; ImmunoTools) or
PerCP-Cy5.5 labelled mAb to human CD127 (mouse IgG1, 5 ml/
tube; eBioscience) for 20 min at RT. After incubation, cells were
treated as previously described [29] and incubated with PE-
labelled mAb to human FOXP3 (mouse IgG1 isotype; 20 ml/tube)
(BD Biosciences, San Jose, CA). In selected experiments, activated
purified Treg (16106/ml) from RA were treated or not with
GXMGal (10 mg/ml) for 18 h and then incubated with PE-
labelled mAb to human FOXP3 (mouse IgG1 isotype; 20 ml/tube)
(BD Biosciences) for 20 min on ice. After incubation, cells were
analyzed by flow cytometry using FACSCalibur (BD Biosciences).
Data are expressed as percentage of positive cells or as mean of
fluorescence intensity (MFI). Autofluorescence and control stain-
ing were evaluated as previously described [29].
Intracellular staining
Activated purified CD4+ T cells (16106/ml) were incubated for
18 or 96 h in the presence or absence of GXMGal (10 mg/ml) or
MTX (10 ng/ml). Brefeldin A (10 mg/ml) was added 2 h after
GXMGal or MTX stimulation [30]. After incubation, cells were
fixed with 1.5% formalin for 10 min at RT, washed and incubated
with APC-labelled mAb to human CD25 (mouse IgG1 isotype;
2 ml/tube; ImmunoTools) for 20 min at RT. After incubation,
cells were treated as previously described [29] and incubated with
PE-labelled mAb to human FOXP3 (mouse IgG1 isotype; 20 ml/
tube) (BD Biosciences), with purified mAbs to human IL-10
(mouse IgG2b isotype, 2 mg/ml) or TGF-b1 (mouse IgG1 isotype,
25 mg/ml) (both Sigma-Aldrich) [29] or in selected experiments
with FITC-labelled mAb to human IFN-c (mouse IgG2b isotype;
10 ml/tube) (Sigma-Aldrich) and with Ab to T-bet (rabbit) (1/50;
GXMGal Improves Treg Function in RA
PLOS ONE | www.plosone.org 2 October 2014 | Volume 9 | Issue 10 | e111163
Santa Cruz) for 20 min on ice followed by Cy3 labelled conjugated
affinity purified secondary antibody (dil. 1/250; Chemicon Int.).
Autofluorescence and control staining were evaluated as previ-
ously described [29].
Apoptosis
Naı¨ve or activated CD4+CD25+ Treg cells were stimulated in
the presence or absence of GXMGal (10 mg/ml) or MTX (10 ng/
ml). The percentage of cells undergoing apoptosis was evaluated
by flow cytometry analysis as previously described [29].
CFSE-based suppression assays
CD4+ responder T cells (Tresp) (16106/ml) were stained with
CFSE (1 mM) (Sigma-Aldrich) according to the manufacturer’s
instructions [31] and then seeded in 96-well culture plates pre-
coated with mAbs to CD3 plus CD28 (both 2 mg/ml) and
activated for 30 min with PHA (10 mg/ml) (Sigma-Aldrich) at
37uC plus 5% CO2 in complete medium. Cells were then washed
and co-cultured for 96 h in the presence or absence of autologous
CD4+CD25+ Treg cells (Tresp/Treg: 16/1) that have been pre-
treated for 18 h in the presence or absence of GXMGal (10 mg/
ml) or MTX (10 ng/ml). After 96 h the suppressive activity of
CD4+CD25+ Treg cells was evaluated by measuring the percent-
age of inhibition of proliferation of CD4+ Tresp cells by flow
cytometry analysis [32]. After 96 h the percentage of CFSE-
stained CD4+CD25+ Treg cells proliferation was determined as
above described.
Statistical analysis
The results reported in the bar graphs are the mean 6 SEM
from triplicate samples of 5–10 different RA patients or Controls.
Mann-Whitney U test was used for statistical analysis, except for
the determination of CD25+FOXP3+ and CD252FOXP3+ cells in
which the statistic was calculated according to Student’s t test.
A value of p,0.05 was considered significant.
Figure 1. GXMGal effect on Treg cell response. Activated PBMC (A and C) or purified CD4+ T cells (B) (both 56106/ml) from Control and RA
were incubated for 2, 18 and 72 h in the presence or absence (NS) of GXMGal (10 mg/ml) or MTX (10 ng/ml). After 2 and 18 h (A) or 18 h (B) of
incubation, cell lysates were analyzed by western blotting. Membranes were incubated with Ab to FOXP3. Actin was used as an internal loading
control. Normalization was shown as mean6 SEM of five independent experiments (A and B). *, p,0.05 (triplicate samples of 5 different Control and
RA; RA treated vs untreated cells). Culture supernatants were collected after 2, 18 and 72 h to test TGF-b1 and IL-10 levels by specific ELISA assays. *,
p,0.05 (triplicate samples of 7 different Control and RA; RA GXMGal-treated vs untreated cells); {, p,0.05 (triplicate samples of 7 different Control
and RA; RA MTX-treated vs untreated cells) (C).
doi:10.1371/journal.pone.0111163.g001
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Results
Firstly, we analyzed the effect of GXMGal on FOXP3
expression in PBMC and CD4+ T cells from RA patients. PBMC
from RA patients and from healthy donors (Control) were treated
with GXMGal or MTX for 2 and 18 h and the expression of
FOXP3 was evaluated. The results showed that GXMGal
markedly induced FOXP3 activation after 2 and 18 h of
incubation, while MTX only after 2 h (Fig. 1A). GXMGal and
MTX treatment did not produce any modulation on PBMC from
Control. GXMGal-induced FOXP3 activation at 18 h was also
confirmed by using purified CD4+ T cells from RA (Fig. 1B).
Furthermore, we analyzed key cytokines such as TGF-b1 and IL-
10 involved in Treg activation [33]. To this purpose PBMC were
treated with GXMGal for 2, 18 and 72 h and the possible
modulation of TGF-b1 and IL-10 production was tested. Both
cytokines were produced at higher levels in culture supernatants of
PBMC from RA patients with respect to Control. The production
of TGF-b1 and IL-10 was further enhanced by GXMGal
treatment after 18 h or 18 and 72 h of incubation respectively
(Fig. 1C). The lack of the increased production of TGF-b1 after
72 h of incubation could be due to the reutilization of this cytokine
by the cells during the incubation period. MTX produced similar
effects.
The proportion of conventional Treg, identified by the
expression of CD25 molecule and FOXP3 (CD25+FOXP3+),
and non-conventional Treg CD252FOXP3+ was tested after
Figure 2. GXMGal effect on different subsets of Treg cells. Activated PBMC (16106/ml) from Control and RA were incubated for 2 h in the
presence or absence (NS) of GXMGal (10 mg/ml) or MTX (10 ng/ml). After incubation, cells were stained for cell surface expression of CD4, CD25 and
CD127 and then intracellular stained for FOXP3. During the acquisition step a population of PBMC enriched of CD4+ T cells was obtained. For analysis,
the CD4+ lymphocytes were gated on PBMC (based on side light scatter and CD4 staining: R1) and analyzed for CD25 and FOXP3 expression
(CD25+FOXP3+: R2 and CD252FOXP3+: R3). The expression of CD127 was shown as FACS histograms in R2 and R3 cells. The gating strategy was
shown (A). The percentage of CD25+FOXP3+ and CD252FOXP3+ cells are shown as mean 6 SEM of ten independent experiments. p= 0.0211
(triplicate samples of 10 different Control and RA; RA GXMGal-treated vs untreated cells); p=0.0357 (triplicate samples of 10 different Control and RA;
RA MTX-treated vs untreated cells (B). The mean of fluorescence intensity (MFI) of FOXP3 in CD25+FOXP3+ and CD252FOXP3+ cells (C) or
magnetically purified Treg (D) from RA after 18 h of GXMGal or MTX treatment was shown as mean 6 SEM of five independent experiments. *, p,
0.05 (triplicate samples of 5 different RA; RA GXMGal-treated vs untreated cells).
doi:10.1371/journal.pone.0111163.g002
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GXMGal treatment in PBMC from RA patients and Control.
CD4+ T cells were gated on PBMC and analyzed for CD25,
FOXP3 and CD127 [33] expression (Fig. 2A). It is known that
Treg CD25+FOXP3+ are CD127low [34]. As shown in Figure 2B
the treatment with GXMGal for 2 h did not modulate the
percentage of CD25+FOXP3+ Treg; however, GXMGal increased
the percentage of non-conventional CD252FOXP3+ Treg. The
prolonged treatment with GXMGal (18 h) did not modulate the
percentage of CD25+FOXP3+ or CD252FOXP3+ Treg (not
shown). Similar effect was observed by using MTX (Fig. 2B).
GXMGal-induced FOXP3 expression at 18 h was evidenced in
CD25+FOXP3+ but not in CD252FOXP3+ Treg from RA
(Fig. 2C). This was confirmed by using magnetically purified Treg
from RA (Fig. 2D). Given that we previously demonstrated that
GXMGal is able to induce apoptosis of activated T cells [19,29],
we evaluated whether GXMGal affects apoptosis of Treg. Our
results showed that treatment with GXMGal or MTX did not
modulate neither apoptosis of naı¨ve and activated RA Treg nor
their proliferation (data not shown).
Given that TGF-b1 and IL-10 production was determined in
PBMC supernatants (Fig. 1C), we analyzed the level of these
cytokines in both CD25+FOXP3+ and CD252FOXP3+ cells. For
the analysis of intracellular cytokines, CD25+FOXP3+ (R1) and
CD252FOXP3+ (R2) were gated on magnetically purified CD4+
T cells (Fig. 3A). After 18 h of incubation, both GXMGal and
MTX induced a significant increase of intracellular TGF-b1
Figure 3. GXMGal effect on Treg cell intracellular cytokines production. Activated purified CD4+ T cells (16106/ml) from RA were incubated
for 18 or 96 h in the presence or absence (NS) of GXMGal (10 mg/ml) or MTX (10 ng/ml). After incubation, cells were stained for cell surface expression
of CD25 then intracellular stained for FOXP3 and TGF-b1 or IL-10. For the analysis of intracellular cytokines, CD25+FOXP3+ (R1) and CD252FOXP3+ (R2)
cells were gated on purified CD4+ T cells. The gating strategy was shown (A). The percentage of intracellular TGF-b1 and IL-10 on CD25+FOXP3+ and
CD252FOXP3 positive cells were shown after 18 h or 96 h (B) as mean 6 SEM of ten independent experiments. *, p,0.05 (triplicate samples of 10
different RA; treated vs untreated cells).
doi:10.1371/journal.pone.0111163.g003
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Figure 4. GXMGal effect on Treg cell suppressive activity. Activated RA purified CD4+ T cells (16106/ml) were stained with CFSE (1 mM) and
then co-cultured for 96 h in the presence or absence of magnetically purified autologous RA Treg cells (Tresp/Treg: 16/1) that have been pre-treated
for 18 h in the presence or absence of GXMGal (10 mg/ml) or MTX (10 ng/ml). After 96 h the suppressive activity of Treg cells was evaluated by
measuring the percentage of inhibition of proliferation of CD4+ responder T cells (Tresp). Representative CFSE histograms show the distribution of
proliferating CFSE-labelled Tresp according to the intensity of the CFSE label from the start of the experiment (Time 0) until 96 h. Given that the initial
cell labelling is fairly homogeneous, each CFSE peak represents a cohort of cells that proceed synchronously through the division rounds. The areas
within each histograms delimitated by the marker represent the percentage of divided CFSE-labeled cells (A). Mean 6 SEM of percentage of
proliferation inhibition is shown as bar graph (B). *, p,0.05 (triplicate samples of 10 different RA; treated vs untreated cells).
doi:10.1371/journal.pone.0111163.g004
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production in purified CD252FOXP3+ cells, but they did not
modulate this cytokine in purified CD25+FOXP3+ cells (Fig 3B).
Moreover, intracellular IL-10 was significantly increased by
GXMGal stimulation in both CD25+FOXP3+ and
CD252FOXP3+ cells. MTX induced a significant increase of
intracellular IL-10 only in CD25+FOXP3+ cells (Fig. 3B). More-
over, when the treatment with GXMGal or MTX was prolonged
till 96 h, a persistence of intracellular increase of IL-10 was
detected only in CD25+FOXP3+ cells. At this time, no modulation
of TGF-b1 was observed in both CD25+FOXP3+ and
CD252FOXP3+ cells (Fig. 3B). Moreover, we verified the in vitro
functional activity of Treg towards autologous responder T cells
(Tresp). RA activated CFSE-labelled Tresp were cultured for 96 h
in the presence or absence of autologous Treg pre-treated for 18 h
with or without GXMGal or MTX. Our data demonstrated that
proliferation of RA Tresp cells was suppressed by Treg and this
effect was significantly potentiated when Treg cells were pre-
treated with GXMGal or MTX (Fig. 4A and B). Since it is
recognized that Th1 cells play an important pro-inflammatory role
in the pathogenesis of RA, the effect of GXMGal on Th1
Figure 5. GXMGal effect on Th1 response. Activated PBMC (A, B and D) (56106/ml) from Control and RA were incubated for 20 min, 2, 18 and
72 h in the presence or absence (NS) of GXMGal (10 mg/ml), MTX (10 ng/ml) or DEX (10 nM). After 20 min of incubation, cell lysates were analyzed by
western blotting. Membranes were incubated with Ab to T-bet. Actin was used as an internal loading control. Normalization was shown as mean 6
SEM of five independent experiments. *, p,0.05 (triplicate samples of 5 different Control and RA; treated vs untreated cells) (A). Culture supernatants
were collected after 2, 18 and 72 h to test IFN-c, IL-12p70 (B) and IL-8 (D) levels by specific ELISA assays. *, p,0.05 (triplicate samples of 7 different
Control and RA; RA GXMGal-treated vs untreated cells); {, p,0.05 (triplicate samples of 7 different Control and RA; RA MTX-treated vs untreated cells);
`, p,0.05 (triplicate samples of 7 different Control and RA; RA DEX-treated vs untreated cells). Activated purified CD4+ T cells (16106/ml) (C) from RA
were stimulated as above described and intracellular stained for T-bet and IFN-c. The percentage of T-bet+/IFN-c+ CD4+ T cells from RA after 18 h of
GXMGal or MTX treatment was shown as mean 6 SEM of five independent experiments. *, p,0.05 (triplicate samples of five different RA; treated vs
untreated cells).
doi:10.1371/journal.pone.0111163.g005
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differentiation was also evaluated. PBMC from RA patients and
Control were treated with GXMGal, MTX and DEX for 20 min.
It is well established that DEX can inhibit Th1 activation [27] and
therefore DEX was used as inhibitor of T-box-containing protein
expressed in T cells (T-bet) activation, exclusively expressed in
Th1 cells. The results showed that GXMGal treatment was able to
significantly suppress T-bet activation in PBMC from RA and
Control. A similar effect was observed with DEX, whereas MTX
produced inhibitory effects only in PBMC from RA patients
(Fig. 5A). To further investigate the role of GXMGal in Th1
response, we analyzed the production of IFN-c and IL-12p70, that
were produced at higher levels in PBMC culture supernatants
from RA compared to Control, after 18 and 72 h or 2, 18 and
72 h, respectively (Fig. 5B). A significant inhibition of IFN-c
production was observed after treatment with GXMGal or MTX
after 18 and 72 h of incubation. As expected, DEX significantly
reduced IFN-c production (Fig. 5B). IL-12p70 was significantly
inhibited by GXMGal at all times tested and by MTX after 18
and 72 h of incubation (Fig. 5B). GXMGal and MTX were also
able to significantly reduce the percentage of T-bet+/IFN-c+
CD4+ T cells from RA after 18 h of incubation (Fig. 5C). We also
tested IL-8 production by PBMC from RA patients and Control
after GXMGal stimulation. Although IL-8 production was higher
in RA than Control PBMC, the levels of this cytokine were not
modulated neither by GXMGal nor MTX treatment at all times
tested (Fig. 5D).
In addition to Th1 activation, Th17 cell activation plays a key
role in the pathogenesis of arthritis [35]. To verify whether a
down-regulation of Th17 occurs in our experimental condition
after GXMGal treatment, we analyzed pSTAT3 activation, a
master regulator of Th17 cells, by using PBMC from RA patients.
FLLL31, a well-known inhibitor of STAT3 activation [36], was
used as negative control. PBMC were stimulated with GXMGal
and the pSTAT3 activator and Th17-related cytokines were
tested. The results showed that pSTAT3 expression was down-
regulated by GXMGal only in PBMC from RA patients, while no
modulation was observed in PBMC from Control (Fig. 6A).
Similar effects were observed after stimulation with FLLL31 or
Figure 6. GXMGal effect on Th17 response. Activated PBMC (A and C) or purified CD4+ T cells (B) (both 56106/ml) from Control and RA were
incubated for 2, 18 and 72 h in the presence or absence (NS) of GXMGal (10 mg/ml), MTX (10 ng/ml) or FLLL31 (5 mM). After 18 h of incubation, cell
lysates were analyzed by western blotting. Membranes were incubated with Abs to pSTAT3 and STAT3. Actin was used as an internal loading control.
Normalization was shown as mean6 SEM of five independent experiments (A) or as one representative experiment of three with similar results (B). *,
p,0.05 (triplicate samples of 5 different Control and RA; RA treated vs untreated cells). Culture supernatants were collected after 2, 18 and 72 h to
test IL-21, IL-22, IL-23, IL-6 and IL-17A levels by specific ELISA assays. *, p,0.05 (triplicate samples of 7 different Control and RA; RA GXMGal-treated vs
untreated cells); {, p,0.05 (triplicate samples of 7 different Control and RA; RA MTX-treated vs untreated cells) (C).
doi:10.1371/journal.pone.0111163.g006
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MTX (Fig. 6A). GXMGal-induced pSTAT3 inactivation at 18 h
was also confirmed by using purified CD4+ T cells from RA
(Fig. 6B). Subsequently, the production of cytokines involved in
Th17 differentiation and activity were analyzed in PBMC from
RA patients. Higher levels of IL-21 were produced by RA PBMC
after 2 and 18 h with respect to Control; higher levels of IL-23 and
IL-6 were produced by PBMC from RA patients after 18 and 72 h
as compared to Control, while a significant increase of IL-22 and
IL-17A was evidenced only after 72 h (Fig. 6C).
We observed an early inhibition (after 2 h) of IL-21 and IL-22
induced by GXMGal in PBMC from RA that persisted for 18 and
72 h. Moreover, the production of IL-6 and IL-23 was signifi-
cantly inhibited after 18 and 72 h, while suppression of IL-17A
was evidenced only after 72 h of GXMGal treatment (Fig. 6C).
MTX showed the same kinetics of IL-22, IL-23, IL-6 and IL-17A
inhibition than that observed for GXMGal, except for IL-21 after
72 h of incubation (Fig. 6C).
Discussion
FOXP3 is thought to be the main marker of Treg, since it plays
a critical role in their development and maturation [37].
Compelling evidence show that FOXP3-deficient mice develop
autoimmune disease [38,39]. The role of Treg in RA has been
partially elucidated and different results have been reported. In
particular, a decreased number of Treg in the blood of RA
patients has been observed [12]; however, other reports show high
levels of circulating conventional CD4+CD25+FOXP3+ Treg cells
in RA [13,14], while additional studies reported an unaltered
number [40]. Because of these controversial results about the
number of circulating Treg cells, the interpretation of the data is
problematic. Nevertheless, compelling evidence has emerged
about the impaired function of these cells in RA patients [6].
Recent investigations revealed that a potentiation of Treg cells is
beneficial in RA [40,41]. In this study we report that the treatment
with GXMGal induces strong and long-lasting increase of FOXP3
expression in RA Treg cells still evident 18 h after stimulation.
This was accompanied by early and transient enhancement of
TGF-b1 production and long-lasting production of IL-10. The
major source of early production of TGF-b1 appeared to be the
CD4+CD252FOXP3+ T cell subset. On the contrary, the early
production of IL-10 seems to be due to both
CD4+CD25+FOXP3+ and CD4+CD252FOXP3+ cells, although
only CD4+CD25+FOXP3+ cells seemed to be responsible of its
long-lasting production. We previously demonstrated that
GXMGal inhibits pro-inflammatory cytokine secretion. Since
the suppressive activity of Treg cells could be counteracted by
inflammatory mediators [42,43], particularly by TNF-a [44], it is
possible that the increased activity of Treg cells induced by
GXMGal could also include the previously described inhibition of
TNF-a [1]. Accordingly, the treatment of RA subjects with an
anti-TNF-a specific antibody was shown to restore Treg cell
function via increased expression of FOXP3 phosphorylation [45].
Similarly, GXMGal could retain beneficial effects similar to those
of anti-TNF-a treatment by influencing Treg cell activity.
GXMGal did not modulate the percentage of
CD4+CD25+FOXP3+ cells, while atypical CD4+CD252FOXP3+
cells appeared to be numerically increased after GXMGal
addition. The percentage of both cells was calculated on CD4+
T cells gated on PBMC, suggesting that the small and not
statistically significant decline of CD4+CD25+FOXP3+, observed
after GXMGal treatment, could at least in part account for the
increased number of CD4+CD252FOXP3+; however it is likely
that besides the shift of CD4+CD25+FOXP3+ into
CD4+CD252FOXP3+, there is also an increase of the
CD4+CD252FOXP3+ cell number per se. Moreover, the signif-
icant increased expression of FOXP3 observed in conventional
RA Treg cells after 18 h of GXMGal treatment clearly
demonstrated that the associated increase of suppressive activity
of all Treg is ascribed to CD4+CD25+FOXP3+ cells. GXMGal
effects on different Treg subsets have been summarized in
Figure 7.
MTX, widely accepted as the ‘‘gold standard’’ treatment in RA,
can affect Treg cells [46] by promoting immunotolerance, despite
the mechanisms are not yet fully elucidated. To our knowledge this
is the first demonstration that MTX treatment increases the
Figure 7. Schematic representation of GXMGal effects on Treg (A) and on Treg/Th17 balance (B).
doi:10.1371/journal.pone.0111163.g007
GXMGal Improves Treg Function in RA
PLOS ONE | www.plosone.org 9 October 2014 | Volume 9 | Issue 10 | e111163
CD4+CD252FOXP3+ fraction of the Treg cell population.
Indeed, we found that the anti-inflammatory effects of GXMGal
on T cells from RA were quite similar to that observed for MTX.
GXMGal differed from MTX just in a few effects, such as
increased production of IL-10 in atypical Treg. The fact that
GXMGal retains multiple regulatory effects similar to that of
MTX and anti-TNF-a agents suggests that GXMGal treatment
may provide the combined beneficial effects of MTX and anti-
TNF-a. Recently, we demonstrated that GXMGal inhibits Th17
activation [20] from RA patients and in the present study we
confirm and extend our previously published data by demonstrat-
ing that the inhibition of Th17 was related to the inhibition of
cytokines such as IL-21, IL-22 and IL-23. Moreover, we also
provide evidence that in peripheral T cells from RA, GXMGal
inhibits Th1 differentiation in terms of T-bet expression and IL-
12p70 and IFN-c production. Therefore, the demonstration of a
Th1-cell suppression combined with a Th17-cell down-regulation
reinforces the idea of a possible therapeutic use of GXMGal in RA
and other inflammatory chronic disorders. GXMGal-treated Treg
cells showed increased suppressive activity manifested by marked
inhibition of effector T-cell proliferation. It is known that the total
Treg cell pool contains a population of CD45RA+ and CD45RO+
Treg cells. CD45RA+ Treg cells were found to be less proliferative
than their CD45RO+ counterparts [47]. In multiple sclerosis an
impairment of suppressive activity of naı¨ve CD45RA+ Treg cells
was reported, thereby suggesting that this population may be
involved in the pathogenesis of autoimmune disorders [48,49].
GXMGal is able to bind to CD45RA and CD45RO isoforms and
we recently suggested that activated T cells expressing the
CD45RO molecule could be the main target of GXMGal-induced
apoptosis [20]. Since the Treg population circulating in RA
belongs to (naı¨ve) resting CD45RA phenotype [50], it is
conceivable that GXMGal binds to these cells and increases their
function without inducing apoptosis. Therefore these results
suggest that in RA patients GXMGal affects Treg function in a
two ways: indirectly by inhibition of inflammatory T cells
differentiation such as Th1 and Th17 and directly by binding to
CD45RA improving activity of Treg. In this study the effect of
GXMGal was specifically observed on Treg population as
demonstrated by: i) enhanced production of TGF-b1, ii) increased
expression of FOXP3 and iii) improved suppression activity on
effector T cells. Future studies will be devoted to evaluate the effect
of GXMGal in an in vivo experimental model of rheumatoid
arthritis. Collectively these data highlight the potential for using
GXMGal to enhance Treg activity, inactivate pathogenic T cells
and halt the disease process in autoimmunity.
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